New Market Research Report: Sweden Pharmaceuticals & Healthcare Report Q1 2011

New Healthcare market report from Business Monitor International: "Sweden Pharmaceuticals & Healthcare Report Q1 2011"
Spread the Word
Listed Under

* Drug
* Pharmaceutical
* Medicines
* Otc
* Generic
* Swedish
* Ratings
* Patented
* Prescription
* Per-capita

* Health
* Medical
* Research

* Massachusetts - US

Dec. 1, 2010 - PRLog -- Despite a compound annual growth rate (CAGR) of 4.61% in local currency terms and 3.77% in US dollar terms from 2004-2009, BMI's outlook for Sweden's drug market is considerably less optimistic over the next five years. Over 2009-2014, a CAGR of -0.95% is projected in local currency terms (which translates into -0.84% in US dollar terms), largely as a result of the impending patent cliff and the consequent consumption of lower-value generic drugs in place of high-value patented drugs. By 2014, pharmaceutical expenditure in Sweden is expected to reach a value of SEK28.94bn (US$3.79bn), falling from SEK30.36bn (US$3.97bn) posted in 2009.

While the Swedish pharmaceutical market is expected to return to positive territory over our longer, 10- year forecast period (posting a local currency CAGR of 1.45%), Sweden is ranked in sixth place in our Pharmaceuticals Business Environment Ratings matrix for Q111 out of the 10 Western European markets. Globally, Sweden is placed 15th, below Brazil and above Poland, out of the total of 83 countries surveyed. While the country's strong emphasis on the regulatory environment is a draw, a major factor affecting the business environment for drugmakers is its small overall market size which, combined with downward pressures on pharmaceutical spending, have conspired to negatively impact the Industry Rewards score in particular. Nevertheless, given its high per capita drug expenditure levels, medicines continue to bring in substantial income for companies operating in the country.

In terms of recent company news, Swedish BioPhausia decided to start a streamlining process in order to focus on the Nordic market. The company will phase out its less profitable operations and products to strengthen its profitability and benefit from new business opportunities arising from events such as the deregulation of the pharmacy market in Sweden. The company is aiming to adapt to changing market situations and better respond to external factors.

Economically speaking, our view that Sweden will be among the top-performing Western European economies through the long term remains unchanged and we have revised up our 2010 real GDP growth forecast to 3.7%. Despite the upward revision, we maintain that a slowdown in headline growth is inevitable as inventory restocking and low base effects wear off in the second half of 2010. We forecast Swedish growth to drop back to 2.6% in 2011, although this will remain well above the 1.4% forecast for the eurozone. Therefore, opportunities for players in the healthcare market in general will remain, as private provision of services is also expected to gain more of a foothold in the country.

For more information or to purchase this report, go to:

Report Table of Contents:

Executive Summary
SWOT Analysis
- Sweden Pharmaceuticals And Healthcare Industry SWOT
- Sweden Political SWOT
- Sweden Economic SWOT
Pharmaceutical Business Environment Ratings
- Table: Western Europe - Regional Pharmaceuticals Business Environment Ratings, Q111
- Rewards
- Risks
Sweden - Market Summary
Regulatory Regime
- Intellectual Property Regime
- Pricing Regime
- Reimbursement Regime
Industry Trends And Developments
- Epidemiology
- Healthcare System
- Clinical Trials Sector
- Medical Devices Sector
Industry Forecast Scenario
- Overall Market Forecast
- Table: Pharmaceutical Sales Indicators 2006-2014
- Healthcare Expenditure Forecast
- Table: Healthcare Expenditure Indicators 2006-2014
- Table: Government Healthcare Expenditure Indicators 2006-2014
- Table: Private Healthcare Expenditure Indicators 2006 -2014
- Macroeconomic Forecast
- Table: Sweden - Economic Activity
- Prescription Drug Market Forecast
- Table: Prescription Drug Sales Indicators 2006-2014
- Patented Drug Market Forecast
- Table: Patented Drug Market Indicators 2006-2014
- Generic Drug Market Forecast
- Table: Generic Drug Sales Indicators 2006-2014
- OTC Medicine Market Forecast
- Table: OTC Medicine Sales Indicators 2006-2014
- Medical Device Market Forecast
- Table: Medical Devices Sales Indicators 2006-2014
- Pharmaceutical Trade Forecast
- Table: Pharmaceutical Export & Import Indicators 2006-2014
- Other Healthcare Data Forecasts
- Key Risks To BMI Forecasts
Competitive Landscape
- Pharmaceutical Manufacturing Sector
- Recent Pharmaceutical Industry Developments
- Pharmaceutical Distribution Sector
Company Profiles
- Indigenous Companies
- Meda
- Swedish Orphan Biovitrum
Country Snapshot: Sweden Demographic Data
- Section 1: Population
- Table: Demographic Indicators, 2005-2030
- Table: Rural/Urban Breakdown, 2005-2030
- Section 2: Education And Healthcare
- Table: Education, 2002-2005
- Table: Vital Statistics, 2005-2030
- Section 3: Labour Market And Spending Power
- Table: Employment Indicators, 2001-2006
- Table: Consumer Expenditure, 2000-2012 (US$)
- Table: Average Annual Wages, 2000-2012
BMI Methodology
- How We Generate Our Pharmaceutical Industry Forecasts
- Risk/Reward Ratings Methodology
- Ratings Overview
- Table: Pharmaceutical Business Environment Indicators
- Weighting
- Table: Weighting Of Components

About Business Monitor International

Business Monitor International (BMI) offers a comprehensive range of products and services designed to help senior executives, analysts and researchers assess and better manage operating risks, and exploit business opportunities, across 175 markets.  BMI offers three main areas of expertise: Country Risk BMI's country risk and macroeconomic forecast portfolio includes weekly financial market reports, monthly regional Monitors, and in-depth quarterly Business Forecast Reports.  Industry Analysis BMI covers a total of 17 industry verticals through a portfolio of services, including in-depth quarterly Country Forecast Reports.  View more research from Business Monitor International at

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at or call us at 1.800.844.8156.

# # #

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.
Email:*** Email Verified
Tags:Drug, Pharmaceutical, Medicines, Otc, Generic, Swedish, Ratings, Patented, Prescription, Per-capita
Industry:Health, Medical, Research
Location:Massachusetts - United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Fast Market Research News
Daily News
Weekly News

Like PRLog?
Click to Share